Sign up for periodic reports and bulletins
FREE access; FREE of commercials; FREE to use
Posted September 20, 2015: by Bill Sardi
Why do women experience a steep increase in heart attacks with the onset of menopause? The obvious answer, without checking the science, is the decline in estrogen production has something to do with the dramatic increase in strokes and heart attacks among post-menopausal women.
Despite the obvious benefits of estrogen replacement, the American Heart Association does not recommend postmenopausal hormone therapy to reduce the risk of coronary heart disease or stroke because some studies have failed to show a reduced risk. A spokesperson for the AHA says: “Estrogen decline isn’t the only reason women face a higher cardiovascular disease risk after reaching menopause. We’re trying to figure the rest of it out.” [American Heart Assn]
Posted September 9, 2015: by Bill Sardi
IP6 phytate is an overlooked nutritional factor that is protective against stiffening (calcification) of the first blood vessel (aorta) outside the heart. Stiffening of the aorta is associated with higher systolic (pumping) blood pressure.
The dietary intake of IP6 was recently measured as determined by excretion in urine among senior adults, with the following results:
Posted September 8, 2015: by Bill Sardi
The claim that the health benefits derived from cholesterol-lowering statin drugs “far out-weigh” potential harms among healthy and high-risk patients continues to be echoed throughout modern medicine. [Current Pharmaceutical Design 2015; British Medical Journal July 17, 2014]
But now a warning has been issued by leading researchers that modern medicine re-think its broadened approach to the use of statin drugs among healthy patients. [Daily Mail UK Sept 6, 2015]
Posted September 6, 2015: by Bill Sardi
This may be the high mark among the 100-plus scientific papers and book chapters that Honorary Professor of Medicine & Surgery STIG BENGMARK, MD, PhD, (Lund University in Sweden) has ever written. His most recent written work is published in the August 2015 edition of the journal Hepatobiliary Surgery & Nutrition, August 2015.
Posted August 27, 2015: by Bill Sardi
Today’s news headlines once again attribute recent declines in coronary heart disease mortality to statin drugs and modern treatments like arterial stents.
Citing a report in the European Heart Journal, The Daily Mail, a British publication, mistakenly claims Great Britain has “one of the best records in Europe” with 184 deaths per 100,000 people for coronary heart disease — a dramatic 46.9% decline over the past 10 years. [European Heart Journal Aug 25, 2015; Daily Mail UK Aug 26, 2015] Yet the chart below reveals Great Britain (United Kingdom) isn’t even in the top 10 countries with the lowest death rate for coronary artery disease.
Posted August 25, 2015: by Bill Sardi
A recently published paper indicates macular degeneration begins with low-grade inflammation that activates microglia, cells that are found in the brain and eyes that dispense with waste products and defend against infection. [Journal Leukocyte Biology Aug 20, 2015]
Posted August 21, 2015: by Bill Sardi
Now that the U.S. Supreme Court has ruled that the Freedom of Speech Amendment in the Constitution truly means “freedom of speech,” the aftershock of this ruling is yet to be realized as it reaches far into America, including dietary supplement labels.
Dietary supplement marketers have long been frustrated over the FDA’s narrow rulings regarding health and disease claims on product labels, particularly for obvious dietary deficiency disorders. For example, the label on a bottle of vitamin C pills cannot say their products allay the many prevalent symptoms of scurvy (vitamin C deficiency) even though they have been well documented for decades.
Posted July 27, 2015: by Bill Sardi
It’s a cardiologist’s dream come true. A newly approved $1200/monthly-injectable drug that dramatically reduces circulating cholesterol levels may become the first $100-200 billion medicine.
That would dwarf the record $9 billion annual sales for Lipitor, the statin cholesterol-lowering drug that was the best selling drug of all time until its patent recently expired. And to add value to the equation, this newly FDA-approved drug may be the first cholesterol-lowering medication to actually save lives, but for different reasons than advertised.
Posted July 13, 2015: by Bill Sardi
Medicare is now going to incentivize death by paying doctors to talk with their patients and families about end-of-life care. Oh, they say this payment policy would only apply to patients and their families who choose to participate on a volunteer basis. But frankly, patients are putty in the hands of doctors. Would the death rate rise commensurate with Medicare payments to physicians over end-of-life issues?
The problem for government overseers is 30% of all Medicare expenditures are attributed to 5% of the beneficiaries who die each year with one third of that occurring in the last month of life. [Health Services Research April 2004]
Of $554 billion spent on Medicare annually, 28 percent, or about $170 billion is spent on patients’ last six months of life. [Medicare Newsgroup June 3, 2012]
Posted May 11, 2015: by Bill Sardi
How does American medicine shed itself of practices that are no longer backed by science and deal with patient fears and at the same time deal with government efforts to produce more jobs in the healthcare sector?
How does American medicine shed itself of practices now invalidated by science? With Medicare facing a $23 trillion shortfall there certainly are no funds for extraneous medical tests and treatments that science no longer substantiates.